Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 7,766 shares, a decrease of 99.0% from the June 15th total of 802,784 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 285,814 shares, the days-to-cover ratio is currently 0.0 days.
Provectus Biopharmaceuticals Price Performance
Provectus Biopharmaceuticals stock traded down $0.00 during trading on Friday, reaching $0.07. The company had a trading volume of 63,360 shares, compared to its average volume of 159,340. The firm’s 50-day simple moving average is $0.07 and its 200 day simple moving average is $0.06. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.10.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.
PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.
Featured Articles
- Five stocks we like better than Provectus Biopharmaceuticals
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
